Nantes, France – June 19, 2024, 6:15 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the General Meeting meeting today has approved all the resolutions proposed by the Board of Directors.
The shareholders also approved the appointment of four new independent directors: Marc Dechamps, Martine George, Markus Goebel and Cécile Nguyen-Cluzel who bring to the Company their extensive leadership experience in the biopharmaceutical industry and strengthen the key skills of the Board of Directors. administration. The new Board has appointed Didier Hoch as Chairman of the Board. He succeeds Dominique Costantini who did not wish to renew his mandate as director during this General Meeting of Shareholders.